Xiangju Kong
YOU?
Author Swipe
View article: Supplementary Figure 7 from Preexisting <i>MEK1</i> Exon 3 Mutations in <sup><i>V600E/K</i></sup><i>BRAF</i> Melanomas Do Not Confer Resistance to BRAF Inhibitors
Supplementary Figure 7 from Preexisting <i>MEK1</i> Exon 3 Mutations in <sup><i>V600E/K</i></sup><i>BRAF</i> Melanomas Do Not Confer Resistance to BRAF Inhibitors Open
PDF file - 76K, B-RAFi and MEKi combinatorial treatments lead to strong synergistic growth inhibition of V600EB-RAF cell lines regardless of concurrent P124SMEK1 expression. M229 and M238 vector vs. MEK1 stable cell lines were cultured wit…
View article: Supplementary Table S2 from Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy
Supplementary Table S2 from Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy Open
PDF file 175K, Catalogue of mechanisms and pathways analyzed and their results
View article: Figure S5 from Recurrent Tumor Cell–Intrinsic and –Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation
Figure S5 from Recurrent Tumor Cell–Intrinsic and –Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation Open
Figure S5
View article: Figure S4 from Recurrent Tumor Cell–Intrinsic and –Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation
Figure S4 from Recurrent Tumor Cell–Intrinsic and –Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation Open
Figure S4
View article: Figure S2 from Recurrent Tumor Cell–Intrinsic and –Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation
Figure S2 from Recurrent Tumor Cell–Intrinsic and –Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation Open
Figure S2
View article: Figure S6 from Recurrent Tumor Cell–Intrinsic and –Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation
Figure S6 from Recurrent Tumor Cell–Intrinsic and –Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation Open
Figure S6
View article: Data from A Novel AKT1 Mutant Amplifies an Adaptive Melanoma Response to BRAF Inhibition
Data from A Novel AKT1 Mutant Amplifies an Adaptive Melanoma Response to BRAF Inhibition Open
BRAF inhibitor (BRAFi) therapy leads to remarkable anti melanoma responses, but the initial tumor shrinkage is commonly incomplete, providing a nidus for subsequent disease progression. Adaptive signaling may underlie early BRAFi resistanc…
View article: Supplementary Table S1-S3 from Recurrent Tumor Cell–Intrinsic and –Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation
Supplementary Table S1-S3 from Recurrent Tumor Cell–Intrinsic and –Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation Open
Supplementary Table S1-S3
View article: Supplementary Figure 1 from Preexisting <i>MEK1</i> Exon 3 Mutations in <sup><i>V600E/K</i></sup><i>BRAF</i> Melanomas Do Not Confer Resistance to BRAF Inhibitors
Supplementary Figure 1 from Preexisting <i>MEK1</i> Exon 3 Mutations in <sup><i>V600E/K</i></sup><i>BRAF</i> Melanomas Do Not Confer Resistance to BRAF Inhibitors Open
PDF file - 181K, Patient tissues harboring concurrent and somatic B-RAF and MEK1 mutations. Chromatograms showing B-RAF exon 15 at V600 codon and MEK1 exon 3 at I111 or P124 codons in patient-matched normal tissue, baseline melanomas (prio…
View article: Supplementary Figure 4 from Preexisting <i>MEK1</i> Exon 3 Mutations in <sup><i>V600E/K</i></sup><i>BRAF</i> Melanomas Do Not Confer Resistance to BRAF Inhibitors
Supplementary Figure 4 from Preexisting <i>MEK1</i> Exon 3 Mutations in <sup><i>V600E/K</i></sup><i>BRAF</i> Melanomas Do Not Confer Resistance to BRAF Inhibitors Open
PDF file - 76K, Relative expression levels of WT vs. P124SMEK1 in the YUKSI B-RAF/MEK1 double-mutant melanoma short-term culture. Genomic DNA (gDNA) and cDNA derived from YUKSI were subjected to exon 3 sequencing by the Sanger method. Rela…
View article: Supplementary Table S5 from Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy
Supplementary Table S5 from Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy Open
XLSX file 12K, Accounting of frequencies of detecting core resistance pathway mechanisms
View article: Supplementary Methods, References and Legends from Recurrent Tumor Cell–Intrinsic and –Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation
Supplementary Methods, References and Legends from Recurrent Tumor Cell–Intrinsic and –Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation Open
Supplementary Methods, References and Legends
View article: Supplementary Figure 3 from Preexisting <i>MEK1</i> Exon 3 Mutations in <sup><i>V600E/K</i></sup><i>BRAF</i> Melanomas Do Not Confer Resistance to BRAF Inhibitors
Supplementary Figure 3 from Preexisting <i>MEK1</i> Exon 3 Mutations in <sup><i>V600E/K</i></sup><i>BRAF</i> Melanomas Do Not Confer Resistance to BRAF Inhibitors Open
PDF file - 188K, Effects of MEK1 P124S co-expression with B-RAF V600K on cellular p-ERK levels and growth inhibitory sensitivities to B-RAFi and MEKi. (A) The YULAC V600KB-RAF melanoma cell line was stably introduced with the doxycycline-r…
View article: Figure S3 from Recurrent Tumor Cell–Intrinsic and –Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation
Figure S3 from Recurrent Tumor Cell–Intrinsic and –Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation Open
Figure S3
View article: Figure S2 from Recurrent Tumor Cell–Intrinsic and –Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation
Figure S2 from Recurrent Tumor Cell–Intrinsic and –Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation Open
Figure S2
View article: Supplementary Table S3 from Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy
Supplementary Table S3 from Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy Open
XLSX file 16K, WES data characteristics including library construction, total reads, base coverage, capture specificity
View article: Supplementary Figures from A Novel AKT1 Mutant Amplifies an Adaptive Melanoma Response to BRAF Inhibition
Supplementary Figures from A Novel AKT1 Mutant Amplifies an Adaptive Melanoma Response to BRAF Inhibition Open
PDF file 1160K, This file contains all supplementary data including key controls experiments for IHC, IHC data quantification, PDGFRbeta IHCs, Western blots of a large melanoma cell line panel, presentation of DTP and DTPP concepts, PDGFRb…
View article: Data from A Novel AKT1 Mutant Amplifies an Adaptive Melanoma Response to BRAF Inhibition
Data from A Novel AKT1 Mutant Amplifies an Adaptive Melanoma Response to BRAF Inhibition Open
BRAF inhibitor (BRAFi) therapy leads to remarkable anti melanoma responses, but the initial tumor shrinkage is commonly incomplete, providing a nidus for subsequent disease progression. Adaptive signaling may underlie early BRAFi resistanc…
View article: Supplementary Figure 7 from Preexisting <i>MEK1</i> Exon 3 Mutations in <sup><i>V600E/K</i></sup><i>BRAF</i> Melanomas Do Not Confer Resistance to BRAF Inhibitors
Supplementary Figure 7 from Preexisting <i>MEK1</i> Exon 3 Mutations in <sup><i>V600E/K</i></sup><i>BRAF</i> Melanomas Do Not Confer Resistance to BRAF Inhibitors Open
PDF file - 76K, B-RAFi and MEKi combinatorial treatments lead to strong synergistic growth inhibition of V600EB-RAF cell lines regardless of concurrent P124SMEK1 expression. M229 and M238 vector vs. MEK1 stable cell lines were cultured wit…
View article: Supplementary Figure 2 from Preexisting <i>MEK1</i> Exon 3 Mutations in <sup><i>V600E/K</i></sup><i>BRAF</i> Melanomas Do Not Confer Resistance to BRAF Inhibitors
Supplementary Figure 2 from Preexisting <i>MEK1</i> Exon 3 Mutations in <sup><i>V600E/K</i></sup><i>BRAF</i> Melanomas Do Not Confer Resistance to BRAF Inhibitors Open
PDF file - 46K, Rapid symptomatic relief in patient 12 treated with GSK2118436/dabrafenib. This patient's right axillary nodal tumor was punch-biopsied at baseline (prior to B-RAFi therapy), showing concurrent B-RAF/MEK1 mutations, and bec…
View article: Data from Preexisting <i>MEK1</i> Exon 3 Mutations in <sup><i>V600E/K</i></sup><i>BRAF</i> Melanomas Do Not Confer Resistance to BRAF Inhibitors
Data from Preexisting <i>MEK1</i> Exon 3 Mutations in <sup><i>V600E/K</i></sup><i>BRAF</i> Melanomas Do Not Confer Resistance to BRAF Inhibitors Open
BRAF inhibitors (BRAFi) induce antitumor responses in nearly 60% of patients with advanced V600E/KBRAF melanomas. Somatic activating MEK1 mutations are thought to be rare in melanomas, but their potential co…
View article: Data from Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy
Data from Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy Open
BRAF inhibitors elicit rapid antitumor responses in the majority of patients with BRAFV600-mutant melanoma, but acquired drug resistance is almost universal. We sought to identify the core resistance pathways and the exte…
View article: Figure S7 from Recurrent Tumor Cell–Intrinsic and –Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation
Figure S7 from Recurrent Tumor Cell–Intrinsic and –Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation Open
Figure S7
View article: Supplementary Figure 5 from Preexisting <i>MEK1</i> Exon 3 Mutations in <sup><i>V600E/K</i></sup><i>BRAF</i> Melanomas Do Not Confer Resistance to BRAF Inhibitors
Supplementary Figure 5 from Preexisting <i>MEK1</i> Exon 3 Mutations in <sup><i>V600E/K</i></sup><i>BRAF</i> Melanomas Do Not Confer Resistance to BRAF Inhibitors Open
PDF file - 144K, Long-term effects of P124SMEK1 expression on population doubling and p-ERK levels. (A) Impact of regulated expression of P124SMEK1 on long-term growth of M238. Stable lines expressing empty vector, FLAG-MEK1 WT or FLAG-MEK…
View article: Figure S3 from Recurrent Tumor Cell–Intrinsic and –Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation
Figure S3 from Recurrent Tumor Cell–Intrinsic and –Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation Open
Figure S3
View article: Supplementary Table S4 from Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy
Supplementary Table S4 from Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy Open
XLS file 56K, List of called variants re-sequenced by Sanger, their gene identities, protein sequences, and the primers used for Sanger sequencing
View article: Supplementary Table S1 from A Novel AKT1 Mutant Amplifies an Adaptive Melanoma Response to BRAF Inhibition
Supplementary Table S1 from A Novel AKT1 Mutant Amplifies an Adaptive Melanoma Response to BRAF Inhibition Open
PDF file 47K, This table provides clinical data for the patient donors
View article: Data from Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy
Data from Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy Open
BRAF inhibitors elicit rapid antitumor responses in the majority of patients with BRAFV600-mutant melanoma, but acquired drug resistance is almost universal. We sought to identify the core resistance pathways and the exte…
View article: Supplementary Figure 1 from Preexisting <i>MEK1</i> Exon 3 Mutations in <sup><i>V600E/K</i></sup><i>BRAF</i> Melanomas Do Not Confer Resistance to BRAF Inhibitors
Supplementary Figure 1 from Preexisting <i>MEK1</i> Exon 3 Mutations in <sup><i>V600E/K</i></sup><i>BRAF</i> Melanomas Do Not Confer Resistance to BRAF Inhibitors Open
PDF file - 181K, Patient tissues harboring concurrent and somatic B-RAF and MEK1 mutations. Chromatograms showing B-RAF exon 15 at V600 codon and MEK1 exon 3 at I111 or P124 codons in patient-matched normal tissue, baseline melanomas (prio…
View article: Supplementary Table S2 from Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy
Supplementary Table S2 from Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy Open
PDF file 175K, Catalogue of mechanisms and pathways analyzed and their results